A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia (Q46099117)
Jump to navigation
Jump to search
scientific article published on June 1, 2011
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia |
scientific article published on June 1, 2011 |
Statements
1 reference
A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia (English)
1 reference
A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia (English)
1 reference
Lu Zhang
1 reference
Sara Kollack-Walker
1 reference
Kimberley Jackson
1 reference
Ludmila Kryzhanovskaya
1 reference
Natalia Jarkova
1 reference
HBBI Study Group
1 reference
Bruce J. Kinon
Brian A. Millen
Olawale O. Osuntokun
Judy E. Williams
1 June 2011
1 reference
31
1 reference
3
1 reference
349-355
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference